Key Developments: West Pharmaceutical Services Inc (WST.N)

WST.N on New York Stock Exchange

75.94USD
1 Aug 2013
Price Change (% chg)

$2.18 (+2.96%)
Prev Close
$73.76
Open
$76.20
Day's High
$76.94
Day's Low
$75.58
Volume
51,833
Avg. Vol
41,647
52-wk High
$76.94
52-wk Low
$46.87

Search Stocks

Latest Key Developments (Source: Significant Developments)

CORRECTION OFFICIAL - West Pharmaceutical Services Inc Lowers FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Thursday, 1 Aug 2013 09:34am EDT 

CORRECTED TO READ - "earnings per share (EPS) in the range of $3.13-$3.28 "... INSTEAD OF ... "earnings per share (EPS) in the range of $3.13-$3.23"... IN THE BODY. West Pharmaceutical Services Inc updated fiscal 2013 guidance and expects consolidated net sales in the range of $1.350-$1.390 billion compared to prior range of $1.360 to $1.400 billion, full-Year diluted earnings per share (EPS) in the range of $3.13-$3.28 compared to prior range of $3.08-$3.23 and Full-Year adjusted diluted EPS of $3.10-$3.25 compared to prior range of $3.05-$3.20. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.37 billion and EPS of $3.14 for fiscal 2013.  Full Article

West Pharmaceutical Services Inc Announces Fourth Quarter 2013 Dividend
Thursday, 1 Aug 2013 09:34am EDT 

West Pharmaceutical Services Inc announced that the fourth-quarter 2013 dividend will increase by $0.01, to $0.20 per share, which will be paid following the stock split at $0.10 per share on a post-split basis. The cash dividend will be paid on November 6, 2013 to shareholders of record on October 23, 2013.  Full Article

West Pharmaceutical Services Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance
Thursday, 2 May 2013 07:00am EDT 

West Pharmaceutical Services Inc announced that for fiscal 2013, it expects consolidated net sales to be in the range of $1,360 to $1,400 million (prior guidance was $1,360 to $1,400), adjusted diluted earnings per share (EPS) to be in the range of $3.05 to $3.20 ( prior guidance was $2.97 to $3.17) and diluted EPS to be in the range of $3.08 to $3.23 ( prior guidance was $3.00 to $3.20 ). The Company's estimated guidance for 2013 includes $6 million in expected sales and development income, and between $0.06 and $0.08 of adjusted diluted EPS, that are associated with customers' research and pre-commercial work with Daikyo Crystal Zenith and other proprietary administration devices, the nature of which increases the risk that actual results may be lower than estimates. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.375 billion and EPS of $3.13 for fiscal 2013.  Full Article

West Pharmaceutical Services Inc Announces Second-Quarter 2013 Dividend
Friday, 15 Mar 2013 04:05pm EDT 

West Pharmaceutical Services Inc announced that its Board has approved the payment of a second-quarter 2013 cash dividend of $0.19 per share. The dividend will be paid on May 1, 2013 to shareholders of record on April 17, 2013.  Full Article

West Pharmaceutical Services Inc Issues FY 2013 Guidance; Revenue Guidance Above Analysts' Estimates
Thursday, 21 Feb 2013 07:14am EST 

West Pharmaceutical Services Inc announced that for fiscal 2013, it expects consolidated net sales in the range of $1.360-$1.400 billion, diluted earnings per share in the range of $3.00-$3.20 and adjusted diluted EPS (adjusted diluted EPS is a Non-GAAP measurement) in the range of $2.97-$3.17. The Company's estimated guidance for fiscal 2013 includes $12 million of expected sales and development income and between $0.11-$0.15 of adjusted diluted EPS, that are associated with customers' research and pre-commercial work with Daikyo Crystal Zenith and other administration devices, the nature of which increases the risk that actual results may be lower than estimates. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.317 billion and EPS of $3.00 for fiscal 2013.  Full Article

West Pharmaceutical Services Inc Announces First Quarter 2013 Dividend
Thursday, 27 Dec 2012 04:15pm EST 

West Pharmaceutical Services Inc announced that its Board has approved the payment of a first-quarter 2013 cash dividend of $0.19 per share. The dividend will be paid on February 6, 2013 to shareholders of record on January 23, 2013.  Full Article

West Pharmaceutical Services Inc Raises Low End Of Prior FY 2012 Revenue Guidance To A Range In Line With Analysts' Estimates; Raises FY 2012 EPS Guidance; Comments On FY 2013 Revenue Guidance;
Thursday, 1 Nov 2012 07:00am EDT 

West Pharmaceutical Services Inc updated fiscal 2012 guidance and expects consolidated net sales in the range of $1.250 to $1.270 billion, compared to prior range of $1.240-$1.270 billion, diluted earnings per share in the range of $2.21 to $2.27, compared to prior range of $2.21 to $2.34 and adjusted diluted earnings per share (EPS) in the range of $2.67 to $2.72 compared to prior range of $2.60-$2.70. For fiscal 2013, it expects sales growth between 4% and 7% on a constant currency basis. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $1.25 billion and EPS of $2.67 for fiscal 2012; revenue of $1.308 billion for fiscal 2013.  Full Article

West Pharmaceutical Services Inc Increases Quarterly Dividend to $0.19
Monday, 1 Oct 2012 04:38pm EDT 

West Pharmaceutical Services Inc announced that its Board of Directors has approved an increase of $0.01 per share in the Company's quarterly cash dividend, to $0.19 per share, beginning in the fourth quarter of 2012. The fourth quarter dividend will be paid on November 7, 2012 to shareholders of record on October 24, 2012.  Full Article

West Pharmaceutical Services Inc Announces Agreement With Janssen Biotech To Develop And Commercialize New Self-injection Technology
Tuesday, 4 Sep 2012 08:10am EDT 

West Pharmaceutical Services Inc announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product. The technology, developed by Janssen Biotech, has been specifically designed to meet the needs of patients by facilitating easier self-injection of pharmaceutical and biologic drug products. West will market the new injection technology under the name SelfDose. West will be responsible for co-developing and handling the commercial scale-up and manufacture of the product, and will have the ability to offer the SelfDose injection technology as part of its expanding portfolio of self-injection technology platforms. The SelfDose injection technology complements West's ConfiDose and SmartDose injection technologies, and offers a solution for improved manual injection.  Full Article

West Pharmaceutical Services, Inc. Raises FY 2012 Guidance
Thursday, 2 Aug 2012 07:00am EDT 

West Pharmaceutical Services, Inc. updated fiscal 2012 guidance and expects consolidated net sales in the range of $1.240-$1.270 billion and diluted earnings per share (EPS) in the range of $2.21 to $2.34 and adjusted EPS in the range of $2.60 to $2.70. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $2.62 for fiscal 2012.  Full Article

REFILE-Exchanges bust trades in West Pharmaceuticals

NEW YORK, May 2 - Nasdaq OMX Group Inc said on Thursday it had determined in conjunction with several exchanges to cancel a host of trades in West Pharmaceuticals Inc

Search Stocks